CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

NetDania - New 12 months High: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

25 7 2024 10:29:14 提供 NetDania Notify

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

22 7 2024 15:05:00 提供 Nasdaq GlobeNewswire

Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions

24 6 2024 15:15:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

06 6 2024 08:45:18 提供 NetDania Notify

NetDania - New 12 months High: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

05 6 2024 12:50:40 提供 NetDania Notify

Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)

03 6 2024 07:00:00 提供 Nasdaq GlobeNewswire

Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)

28 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

01 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Corcept Completes Enrollment in Phase 4 CATALYST Trial

29 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

24 4 2024 15:05:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

22 4 2024 08:59:41 提供 NetDania Notify

Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome

22 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

15 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

08 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

01 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

15 2 2024 15:07:00 提供 Nasdaq GlobeNewswire

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

15 2 2024 15:02:00 提供 Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

08 2 2024 15:05:00 提供 Nasdaq GlobeNewswire

Corcept Appoints Roberto Vieira as President, Oncology

29 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program

08 1 2024 07:00:01 提供 Nasdaq GlobeNewswire